KYMERA THERAPEUTICS INC (KYMR) Stock Analyst Ratings
USA - NASDAQ:KYMR - US5015751044 - Common Stock
61.6 USD
+2.94 (+5.01%)
ChartMill assigns a Buy % Consensus number of 88% to KYMR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 69.8. This target is 13.31% above the current price.
KYMR was analyzed by 29 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about KYMR.
In the previous month the buy percentage consensus was at a similar level.
KYMR was analyzed by 29 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-05 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-22 | BTIG | Maintains | Buy -> Buy |
| 2025-10-21 | Mizuho | Initiate | Outperform |
| 2025-10-17 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-01 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-30 | Truist Securities | Maintains | Buy -> Buy |
| 2025-09-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-17 | Barclays | Initiate | Overweight |
| 2025-09-16 | RBC Capital | Initiate | Outperform |
| 2025-06-27 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-06-26 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-06-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-03 | B. Riley Securities | Upgrade | Neutral -> Buy |
| 2025-06-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-06-03 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2025-05-20 | Stifel | Reiterate | Buy |
| 2025-05-13 | UBS | Maintains | Buy -> Buy |
| 2025-05-12 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-05-12 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-03-13 | Citigroup | Initiate | Buy |
| 2025-02-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-21 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2024-12-27 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-12-10 | BTIG | Initiate | Buy |
| 2024-12-06 | BMO Capital | Initiate | Market Perform |
| 2024-12-02 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2024-11-18 | Stephens & Co. | Initiate | Overweight |
| 2024-11-06 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
KYMERA THERAPEUTICS INC / KYMR FAQ
Can you provide the average price target for KYMERA THERAPEUTICS INC stock?
29 analysts have analysed KYMR and the average price target is 69.8 USD. This implies a price increase of 13.31% is expected in the next year compared to the current price of 61.6.
Can you provide the consensus rating for KYMERA THERAPEUTICS INC stock?
The consensus rating for KYMERA THERAPEUTICS INC (KYMR) is 87.5862 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed KYMERA THERAPEUTICS INC (KYMR)?
The number of analysts covering KYMERA THERAPEUTICS INC (KYMR) is 29.